149 related articles for article (PubMed ID: 32472195)
1. Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; Holth A; Dong HP
Virchows Arch; 2020 Nov; 477(5):677-685. PubMed ID: 32472195
[TBL] [Abstract][Full Text] [Related]
2. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
Sherman-Samis M; Onallah H; Holth A; Reich R; Davidson B
Gynecol Oncol; 2019 Jun; 153(3):651-660. PubMed ID: 30904337
[TBL] [Abstract][Full Text] [Related]
3. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
Broner EC; Tropé CG; Reich R; Davidson B
Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
[TBL] [Abstract][Full Text] [Related]
4. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.
Onallah H; Catane LJ; Tropé CG; Hetland Falkenthal TE; Reich R; Davidson B
Virchows Arch; 2018 Oct; 473(4):463-470. PubMed ID: 30032361
[TBL] [Abstract][Full Text] [Related]
5. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
6. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
Davidson B; Bock AJ; Holth A; Nymoen DA
Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
[TBL] [Abstract][Full Text] [Related]
7. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
[TBL] [Abstract][Full Text] [Related]
8. Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma.
Harel-Dassa K; Yedgar S; Tropé CG; Davidson B; Reich R
Hum Pathol; 2017 Apr; 62():115-121. PubMed ID: 28087476
[TBL] [Abstract][Full Text] [Related]
9. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
Filippov-Levy N; Cohen-Schussheim H; Tropé CG; Hetland Falkenthal TE; Smith Y; Davidson B; Reich R
Gynecol Oncol; 2018 Mar; 148(3):559-566. PubMed ID: 29310950
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
11. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
12. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
Davidson B
Hum Pathol; 2016 Dec; 58():123-127. PubMed ID: 27589896
[TBL] [Abstract][Full Text] [Related]
13. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
14. MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma.
Nymoen DA; Slipicevic A; Holth A; Emilsen E; Hetland Falkenthal TE; Tropé CG; Reich R; Flørenes VA; Davidson B
Hum Pathol; 2016 Aug; 54():74-81. PubMed ID: 27063471
[TBL] [Abstract][Full Text] [Related]
15. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
[TBL] [Abstract][Full Text] [Related]
16. Expression of Nestin and CD133 in serous ovarian carcinoma.
Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
[TBL] [Abstract][Full Text] [Related]
17. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
Dos Santos MV; Holth A; Bischof K; Davidson B
Clin Exp Metastasis; 2024 Feb; 41(1):69-76. PubMed ID: 38141113
[TBL] [Abstract][Full Text] [Related]
18. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
[TBL] [Abstract][Full Text] [Related]
20. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
